OccuRx is a biopharmaceutical company focused on innovative therapeutic strategies for diabetes complications associated with inflammation and fibrosis.

Diabetes continues to be a major public health problem and has many serious complications that affect multiple organs of the body particularly the eye, kidneys and blood vessels. Overtime damage to blood vessels of the eyes and filtering units in the kidneys occurs, leading to chronic inflammation, microvascular changes and irreversible fibrosis. Ultimately this can result in both diabetic kidney and eye disease, both of which are associated with significant morbidity and/or mortality including end stage kidney disease and, in the eye, diabetic retinopathy and blindness. With no cure available, intensive research is required to develop novel treatment possibilities.

At OccuRx we are dedicated to identifying and validating novel targets that treat and prevent fibrosis that lead to disease progression and end organ failure. The company’s most advanced molecule drug candidate, OCX063, is being developed as a first-in-class oral therapy for the treatment for both kidney and ocular diseases. OCX063, is a small molecule drug with the potential to prevent the growth of new and abnormal blood vessels and reduce inflammation.

OccuRx was established in 2014 with venture funding from Brandon BioCatalyst (formerly the Medical Research Commercialisation Fund/MRCF), Brandon Capital Partners and Uniseed.